ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.18), FiscalAI reports.
ENDRA Life Sciences Stock Down 1.7%
Shares of ENDRA Life Sciences stock opened at $4.35 on Tuesday. The firm has a market cap of $6.52 million, a PE ratio of -0.69 and a beta of -0.07. ENDRA Life Sciences has a 12-month low of $2.96 and a 12-month high of $6.95. The company’s fifty day simple moving average is $5.32 and its two-hundred day simple moving average is $4.82.
Analyst Ratings Changes
Separately, Weiss Ratings cut ENDRA Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, November 2nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $25.00.
View Our Latest Stock Report on ENDRA Life Sciences
About ENDRA Life Sciences
ENDRA Life Sciences is a medical technology company developing imaging tools for the assessment of liver disease. Its technology is designed to provide clinicians with a non-invasive way to evaluate liver tissue and support the monitoring of conditions such as fatty liver disease. The company’s lead platform, TAEUS (Thermo-Acoustic Enhanced Ultrasound), combines radiofrequency energy with ultrasound to measure tissue characteristics, including liver fat. ENDRA is developing the system as an alternative or complement to existing approaches to liver assessment.
Recommended Stories
- Five stocks we like better than ENDRA Life Sciences
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
